https://doi.org/10.4081/monaldi.2021.1816

The initial experience of COVID-19 vaccination from a tertiary care centre of India

Vol. 91 No. 4 (2021)
Submitted: February 23, 2021
Accepted: March 19, 2021
Published: March 31, 2021
COVID-19, Vaccine , Safety, AEFI, Initial
Abstract Views: 4652
PDF: 2476
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

RK Srivastava
Safdarjung Hospital, New Delhi, India.
Pranav Ish
pranavish2512@gmail.com
https://orcid.org/0000-0003-1701-4970
Department of Pulmonary, Critical Care and Sleep Medicine, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
*Safdarjung COVID-19 Vaccination group
Safdarjung Hospital, New Delh, India.

To the Editor

Drugs Controller General of India (DCGI) has approved the Bharat biotech vaccine against COVID-19, which is a locally manufactured inactivated vaccine named ''COVAXIN'' in collaboration with the Indian council of medical research (ICMR) on 3rd  January 2021 for emergency use along with the "Covishield" Oxford-AstraZeneca vaccine manufactured locally by the Serum Institute of India...

*The Safdarjung COVID-19 Vaccination group:

KR Meena (Professor, Paediatrics), U Venkatesh (Assistant Professor, Community Medicine), Pushpa Kumari (Associate Professor, Medicine), Sonal Burman (Specialist, Medicine), Neeraj Kumar Gupta (Professor and Head, Pulmonary Medicine), Nitesh Gupta (Assistant Professor, Pulmonary Medicine), Rohit Kumar (Assistant Professor, Pulmonary Medicine), Swetabh Purohit (Senior resident, Pulmonary Medicine), Arjun Ramaswamy (Senior resident, Pulmonary Medicine)

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Ministry of Health and Family Welfare. Press statement by the Drugs Controller General of India (DCGI) on restricted emergency approval of COVID-19 virus vaccine. Jan 3, 2021. Accessed: January 5, 2021. Available from: https://pib.gov.in/PressReleseDetail.aspx?PRID=1685761
Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021;21:39-51. DOI: https://doi.org/10.1016/S1473-3099(20)30831-8
Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv 2020.12.21.20248643. DOI: https://doi.org/10.1101/2020.12.21.20248643
The Hindu [Internet]. Coronavirus. Covaxin efficacy is 81%, works against variants. Accessed: 18 March 2021. Available from: Downloaded from https://www.thehindu.com/sci-tech/health/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy/article33980224.ece
Government of India. Operational Guideline COVID-19 Vaccines [Internet]. New Delhi; 2021. Accessed: 22 February 2021. Available from: https://www.mohfw.gov.in/pdf/COVID19VaccineOG111Chapter16.pdf
The Times of India [Internet]. Covid-19: India vaccinates 54.7% healthcare workers registered on CoWin platform. Accessed: 22 February 2021. Available from: https://timesofindia.indiatimes.com/india/covid-19-india-vaccinates-54-7-healthcare-workers-registered-on-cowin-platform/articleshow/80725869.cms
WHO. Classification of AEFIS. Accessed: 22 February 2021. Available from: https://vaccine-safety-training.org/classification-of-aefis.html

How to Cite

Srivastava, RK, Pranav Ish, and *Safdarjung COVID-19 Vaccination group. 2021. “The Initial Experience of COVID-19 Vaccination from a Tertiary Care Centre of India”. Monaldi Archives for Chest Disease 91 (4). https://doi.org/10.4081/monaldi.2021.1816.
Copyright (c) 2021 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.


Similar Articles

<< < 3 4 5 6 7 8 9 10 11 12 > >> 

You may also start an advanced similarity search for this article.